Transitioning to Human-Relevant Science: Why the Shift to ACF is Now.
The regulatory landscape is changing rapidly.
The U.S. Food and Drug Administration (FDA) has fundamentally shifted its approach, phasing out the requirement for animal-based testing in drug development. As outlined in the FDA’s new roadmap, the agency now encourages New Approach Methodologies (NAMs)—such as AI-based models, organ-on-chip systems, and organoids—to generate more human-relevant safety data.
"In just the past year, I’ve seen a clear shift across the scientific community: researchers are actively searching for animal-free solutions. Animal-free products are quickly becoming the new standard for good science,"
Dr. Peter Frost
CEO PELOBiotech GmbH
Are you still relying on animal derived components or products for your human research?
Working with animal compounds or sera is from the ethically point of view problematic and is in many cases not predictive enough. At the same time animal products carry the risk of unknown infectious pathogens. As a first step to overcome these issues is it to avoid the usage of animal derived products for human research. This is in line with the guidelines of the FDA/NIH published last year. Classical used materials widely use are animal serum (FCS), Matrigel and other animal proteins mixtures.
For the production of Matrigel alone, approximately 3.6 million mice are sacrificed every year. Approx. 1 – 2 million bovines fetuses are needed for this which leads to approx. 800.000 liter FCS.
A second final step will be to use only defined & animal-free solutions e.g. chemically defined media or defined & purified enzymes for tissue dissociation. Not using black boxes will significantly increase predictivity and reproducibility of experimental designs.
PELOBiotech offers a hand-picked portfolio of Animal Component-Free (ACF) & chemically defined products—made by scientists for scientists—to eliminate biological variability and deliver the lean, consistent data your research demands.
The Scientific Imperative
The core challenge with traditional components like Fetal Bovine Serum (FBS) lies in their ill-defined nature. Our ACF portfolio addresses these limitations.
PELOBiotech's Animal Component-Free Portfolio
Our portfolio covers every critical step of your cell culture workflow to ensure continuity and safety:
- ACF/Xeno-Free Media & Supplements: Including UltraGROTM product family (hPL), human AB serum and specialized, chemically defined media for sensitive cell types like MSCs and iPSCs.
- Defined Extracellular matrix proteins (ECMs) as Coating Solutions or Hydrogels: Natural human organ derived ECMs, synthetic and recombinant matrices, such as human protein-based hydrogels by Metatissue or human-derived collagens and laminin by THT Biomaterials, to create physiologically relevant 2D/3D models (e.g., organoids).
- ACF Tissue Dissociation & Cryopreservation: ACF enzymatic tissue dissociation and defined (serum-free & protein-free) freezing solutions to protect cell viability from harvest to storage.
- ACF Solutions of cell passaging
- Recombinant Growth Factors & Cytokines: High-purity proteins, produced to ensure high biological activity and zero animal contamination.
Streamlined Logistics for Your Research
We understand that your research doesn't stop.
Our logistics team handles your orders with due diligence, ensuring that even overseas shipments are provided with sufficient dry ice. We keep a close eye on your delivery—even on weekends—to ensure that regulatory requirements and ACF-declarations are handled with priority for a seamless supply chain.
Ready to transition your protocol?
Don't let undefined components hold back your scientific breakthroughs. Our team of PhD-level application specialists is here to help you seamlessly transition to animal-free systems.